Inverse association of plasma IL-13 and inflammatory chemokines with lung function impairment in stable COPD: A cross-sectional cohort study

Respiratory Research

Volumn 8, Issue , 2007, Pages

  Lee, Janet S ^a   Rosengart, Matthew R ^b   Kondragunta, Venkateswarlu ^a   Zhang, Yingze ^a   McMurray, Jessica ^a   Branch, Robert A ^b   Choi, Augustine M K ^a   Sciurba, Frank C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 13; PLASMA PROTEIN;

ARTICLE; BLOOD; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; SMOKING;

BIOLOGICAL MARKERS; BLOOD PROTEINS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INTERLEUKIN-13; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SMOKING;

EID: 38449117706     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-8-64     Document Type: Article

References (57)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001, 163(5):1256-1276.
2. Rabe K, Barnes P, Buist S, Calverley PM, Fabbri L, Fukuchi Y, MacNee W, Rodriguez-Roisin R, Zielinski I. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease Workshop Executive Summary, 2005 Update. GOLD website wwwgoldcopdorg 2005,
3. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59(7):574-580. 10.1136/thx.2003.019588, 15223864.
4. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003, 114(9):758-762. 10.1016/S0002-9343(03)00185-2, 12829203.
5. Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005, 127(2):558-564. 10.1378/chest.127.2.558, 15705996.
6. Man SF, Sin DD. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2(1):78-82. 10.1513/pats.200406-034MS, 16113473.
7. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170(7):760-765. 10.1164/rccm.200404-543OC, 15229100.
8. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991, 144(5):1202-1218.
9. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995, 152(3):1107-1136.
10. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J 2005, 26(2):319-338. 10.1183/09031936.05.00034805, 16055882.
11. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26(4):720-735. 10.1183/09031936.05.00034905, 16204605.
12. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981, 123(2):185-189.
13. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981, 123(6):659-664.
14. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(4):981-987. 10.1158/1055-9965.EPI-04-0404, 15824174.
15. Lee JS, Wurfel MM, Matute-Bello G, Frevert CW, Rosengart MR, Ranganathan M, Wong VW, Holden T, Sutlief S, Richmond A, Peiper S, Martin TR. The Duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation. J Immunol 2006, 177(11):8086-8094.
16. Wurfel MM, Park WY, Radella F, Ruzinski J, Sandstrom A, Strout J, Bumgarner RE, Martin TR. Identification of high and low responders to lipopolysaccharide in normal subjects: an unbiased approach to identify modulators of innate immunity. J Immunol 2005, 175(4):2570-2578.
17. Yasuda N, Gotoh K, Minatoguchi S, Asano K, Nishigaki K, Nomura M, Ohno A, Watanabe M, Sano H, Kumada H, Sawa T, Fujiwara H. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med 1998, 92(8):993-999. 10.1016/S0954-6111(98)90343-2, 9893764.
18. Takabatake N, Arao T, Sata M, Inoue S, Abe S, Shibata Y, Kubota I. Circulating levels of soluble Fas ligand in cachexic patients with COPD are higher than those in non-cachexic patients with COPD. Intern Med 2005, 44(11):1137-1143. 10.2169/internalmedicine.44.1137, 16357450.
19. Takabatake N, Nakamura H, Inoue S, Terashita K, Yuki H, Kato S, Yasumura S, Tomoike H. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease. Respir Med 2000, 94(12):1215-1220. 10.1053/rmed.2000.0941, 11192958.
20. Andelid K, Bake B, Rak S, Linden A, Rosengren A, Ekberg-Jansson A. Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms . Respir Med 2007, 101:888-895 2007, 101:888-95. 8564092.
21. Capelli A, Di Stefano A, Gnemmi I, Balbo P, Cerutti CG, Balbi B, Lusuardi M, Donner CF. Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J 1999, 14(1):160-165. 10.1034/j.1399-3003.1999.14a27.x, 10489845.
22. Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, Fabbri LM, Barnes N, Saetta M, Jeffery PK. Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001, 164(1):109-116.
23. Bocchino V, Bertorelli G, Bertrand CP, Ponath PD, Newman W, Franco C, Marruchella A, Merlini S, Del Donno M, Zhuo X, Olivieri D. Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy 2002, 57(1):17-22. 10.1034/j.1398-9995.2002.13230.x, 11991282.
24. Nocker RE, Schoonbrood DF, van de Graaf EA, Hack CE, Lutter R, Jansen HM, Out TA. Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 1996, 109(2):183-191.
25. Tanino M, Betsuyaku T, Takeyabu K, Tanino Y, Yamaguchi E, Miyamoto K, Nishimura M. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema. Thorax 2002, 57(5):405-411. 10.1136/thorax.57.5.405, 11978916.
26. Grumelli S, Corry DB, Song LZ, Song L, Green L, Huh J, Hacken J, Espada R, Bag R, Lewis DE, Kheradmand F. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004, 1(1):e8. 523885, 15526056, 10.1371/journal.pmed.0010008.
27. Elias JA, Kang MJ, Crouthers K, Homer R, Lee CG. State of the art. Mechanistic heterogeneity in chronic obstructive pulmonary disease: insights from transgenic mice. Proc Am Thorac Soc 2006, 3(6):494-498. 10.1513/pats.200603-068MS, 16921126.
28. Barcelo B, Pons J, Fuster A, Sauleda J, Noguera A, Ferrer JM, Agusti AG. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2006, 145(3):474-479. 1809717, 16907916, 10.1111/j.1365-2249.2006.03167.x.
29. Barnes PJ, Cosio MG. Characterization of T lymphocytes in chronic obstructive pulmonary disease. PLoS Med 2004, 1(1):e20. 523839, 15526047, 10.1371/journal.pmed.0010020.
30. Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DJ. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164(8 Pt 1):1414-1418.
31. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wouters EF. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002, 166(9):1218-1224. 10.1164/rccm.2202023, 12403691.
32. Ferroni P, Basili S, Alessandri C, Vieri M, Martini F, Belogi A, Pulcinelli FM, Cordova C, Gazzaniga PP. Proinflammatory cytokines and hemostatic system in patients with chronic obstructive pulmonary disease. Platelets 1997, 8(4):255-259. 10.1080/09537109777294, 16793656.
33. Takeyama K, Jung B, Shim JJ, Burgel PR, Dao-Pick T, Ueki IF, Protin U, Kroschel P, Nadel JA. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am J Physiol Lung Cell Mol Physiol 2001, 280(1):L165-72.
34. Nadel JA. Role of epidermal growth factor receptor activation in regulating mucin synthesis. Respir Res 2001, 2(2):85-89. 59573, 11686870, 10.1186/rr43.
35. Nadel JA, Burgel PR. The role of epidermal growth factor in mucus production. Curr Opin Pharmacol 2001, 1(3):254-258. 10.1016/S1471-4892(01)00045-5, 11712748.
36. Kranenburg AR, De Boer WI, Van Krieken JH, Mooi WJ, Walters JE, Saxena PR, Sterk PJ, Sharma HS. Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002, 27(5):517-525.
37. Kranenburg AR, Willems-Widyastuti A, Mooi WJ, Saxena PR, Sterk PJ, de Boer WI, Sharma HS. Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2, and FGFR-1. J Pathol 2005, 206(1):28-38. 10.1002/path.1748, 15772985.
38. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004, 56(4):515-548. 10.1124/pr.56.4.2, 15602009.
39. Plantier L, Marchand-Adam S, Marchal-Somme J, Leseche G, Fournier M, Dehoux M, Aubier M, Crestani B. Defect of hepatocyte growth factor production by fibroblasts in human pulmonary emphysema. Am J Physiol Lung Cell Mol Physiol 2005, 288(4):L641-7. 10.1152/ajplung.00249.2004, 15579628.
40. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000, 106(11):1311-1319. 387249, 11104784.
41. Bio-Rad Laboratories I. Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev. B, Bulletin # 2861. wwwbio-radcom
42. de Jager W, Rijkers GT. Solid-phase and bead-based cytokine immunoassay: a comparison. Methods 2006, 38(4):294-303. 10.1016/j.ymeth.2005.11.008, 16481197.
43. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174(8):867-874. 10.1164/rccm.200604-506OC, 16799074.
44. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J 2005, 26(5):948-968. 10.1183/09031936.05.00035205, 16264058.
45. Shim JJ, Dabbagh K, Ueki IF, Dao-Pick T, Burgel PR, Takeyama K, Tam DC, Nadel JA. IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. Am J Physiol Lung Cell Mol Physiol 2001, 280(1):L134-40.
46. Ma B, Liu W, Homer RJ, Lee PJ, Coyle AJ, Lora JM, Lee CG, Elias JA. Role of CCR5 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 2006, 176(8):4968-4978.
47. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999, 103(6):779-788. 408149, 10079098.
48. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, Riese RJ, Chapman HA, Shapiro SD, Elias JA. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 2000, 106(9):1081-1093. 301418, 11067861.
49. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52(1):145-176.
50. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002, 57(7):590-595. 10.1136/thorax.57.7.590, 12096201.
51. Fukakusa M, Bergeron C, Tulic MK, Fiset PO, Al Dewachi O, Laviolette M, Hamid Q, Chakir J. Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa. J Allergy Clin Immunol 2005, 115(2):280-286. 10.1016/j.jaci.2004.10.036, 15696082.
52. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000, 356(9240):1480-1485. 10.1016/S0140-6736(00)02872-5, 11081531.
53. Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, Bellettato CM, Papi A, Corbetta L, Zuin R, Sinigaglia F, Fabbri LM. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 165(10):1404-1409. 10.1164/rccm.2107139, 12016104.
54. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992, 80(8):2012-2020.
55. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2645-2653. 10.1056/NEJMoa032158, 15215480.
56. Albertine KH, Soulier MF, Wang Z, Ishizaka A, Hashimoto S, Zimmerman GA, Matthay MA, Ware LB. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol 2002, 161(5):1783-1796. 1850801, 12414525.
57. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994, 263(5154):1759-1762. 10.1126/science.7510905, 7510905.